BLUEJET Blue Jet Healthcare Q1 FY26 results (Apr–Jun 2025) and concall
Blue Jet Healthcare reported a strong Q1 FY26 with revenue up 118% YoY to ₹354.8 crores and PAT up 114% YoY to ₹91.2 crores. Despite a QoQ decline in EBITDA and gross margins due to inventory adjustments and product mix, management expressed confidence in sustaining growth and margins for FY26, driven by capacity expansions and a robust CDMO pipeline. The company is advancing significant capex for new facilities and R&D, aiming to add 1,000 KL capacity in the next 2-3 years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 208 | 318 | 340 | 355 |
| EBITDA | 69 | 124 | 140 | 121 |
| Net profit | 58 | 99 | 110 | 91 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
